Compare STRO & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRO | REAL |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 1.7B |
| IPO Year | 2018 | 2019 |
| Metric | STRO | REAL |
|---|---|---|
| Price | $10.75 | $16.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $18.29 | $15.29 |
| AVG Volume (30 Days) | 123.2K | ★ 2.7M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $105,646,000.00 | ★ $662,789,000.00 |
| Revenue This Year | $63.08 | $17.10 |
| Revenue Next Year | N/A | $10.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.30 |
| 52 Week Low | $5.23 | $4.61 |
| 52 Week High | $21.50 | $16.24 |
| Indicator | STRO | REAL |
|---|---|---|
| Relative Strength Index (RSI) | 81.15 | 68.97 |
| Support Level | $8.49 | $15.13 |
| Resistance Level | $11.09 | $16.08 |
| Average True Range (ATR) | 0.83 | 0.78 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 89.41 | 96.11 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.